N. S. Giliazetdinova
N. S. Giliazetdinova has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Vitaliy Vladimirovich Omelyanovskiy
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education
4 shared publications - I. I. Khayrullin
Pirogov City Clinical Hospital No. 1; Russian Medical Academy of Continuing Professional Education
2 shared publications - Ilya Aleksandrovich Mikhailov
Lomonosov Moscow State University
2 shared publications - Roman V. Gostishev
Pirogov Moscow City Clinical Hospital No. 1
2 shared publications - A.A. Matomorova1 shared publication
- A.N. Telesheva1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 215-223
Estimation of the socio-economic burden of obesity in the Russian Federation
Objective : To estimate the direct medical costs associated with the treatment of adult patients with obesity in the Russian Federation, including the costs of pharmacotherapy for obesity, management of comorbidities and hospitalizations due to specific obesity-related complication. Material and methods. A mathematical model was developed to analyze the direct medical costs of pharmacotherapy for obesity and related comorbidities over a 1-year time horizon. The analysis included adults aged 18–69 years with obesity (body mass index (BMI) ≥30 kg/m²); a subgroup of individuals with BMI ≥35 kg/m² was analyzed separately. The target population size was determined using national epidemiological data, stratified by sex, age, and obesity class. The model evaluated the costs of pharmacotherapy for obesity, management of comorbid conditions, and hospitalizations associated with type 2 diabetes mellitus, coronary heart disease, and arterial hypertension. Treatment costs were calculated based on dosing regimens, the State Register of Maximum Selling Prices, and public procurement data; hospitalization costs were estimated using diagnosis-related groups. Results . The estimated number of adults with obesity was 21.64 million, including 5.45 million individuals with BMI ≥35 kg/m². In the modeled scenario of universal drug coverage, annual pharmacotherapy costs were estimated at 3.1 trillion rubles for the overall population and 778 billion rubles for the subgroup with BMI ≥35 kg/m². The estimated number of comorbidity cases was 4.44 million for coronary heart disease, 15.2 million for arterial hypertension, and 7.03 million for type 2 diabetes mellitus. Pharmacotherapy costs for these conditions amounted to 69, 324, and 396 billion rubles, respectively. Annual hospitalization costs were estimated at 377 billion rubles for type 2 diabetes mellitus and 89 billion rubles for coronary heart disease. Conclusion . The management of adults with obesity and comorbid conditions within the Russian healthcare system is associated with substantial direct medical costs. Reducing this burden requires a combination of prevention, early detection, and long-term patient management.
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 215-223
Open AccessEstimation of the socio-economic burden of obesity in the Russian Federation
Objective : To estimate the direct medical costs associated with the treatment of adult patients with obesity in the Russian Federation, including the costs of pharmacotherapy for obesity, management of comorbidities and hospitalizations due to specific obesity-related complication. Material and methods. A mathematical model was developed to analyze the direct medical costs of pharmacotherapy for obesity and related comorbidities over a 1-year time horizon. The analysis included adults aged 18–69 years with obesity (body mass index (BMI) ≥30 kg/m²); a subgroup of individuals with BMI ≥35 kg/m² was analyzed separately. The target population size was determined using national epidemiological data, stratified by sex, age, and obesity class. The model evaluated the costs of pharmacotherapy for obesity, management of comorbid conditions, and hospitalizations associated with type 2 diabetes mellitus, coronary heart disease, and arterial hypertension. Treatment costs were calculated based on dosing regimens, the State Register of Maximum Selling Prices, and public procurement data; hospitalization costs were estimated using diagnosis-related groups. Results . The estimated number of adults with obesity was 21.64 million, including 5.45 million individuals with BMI ≥35 kg/m². In the modeled scenario of universal drug coverage, annual pharmacotherapy costs were estimated at 3.1 trillion rubles for the overall population and 778 billion rubles for the subgroup with BMI ≥35 kg/m². The estimated number of comorbidity cases was 4.44 million for coronary heart disease, 15.2 million for arterial hypertension, and 7.03 million for type 2 diabetes mellitus. Pharmacotherapy costs for these conditions amounted to 69, 324, and 396 billion rubles, respectively. Annual hospitalization costs were estimated at 377 billion rubles for type 2 diabetes mellitus and 89 billion rubles for coronary heart disease. Conclusion . The management of adults with obesity and comorbid conditions within the Russian healthcare system is associated with substantial direct medical costs. Reducing this burden requires a combination of prevention, early detection, and long-term patient management.
- 17 March 2026
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 48 (1) , 48-58
Comparison of disease prioritization approaches for piloting value-based healthcare. Experience of international projects
Despite multiple international projects aimed at developing standards and pilot introduction of value-based healthcare, there is no systematic understanding of approaches for selection of priority diseases or conditions at baseline phase of implementing this model. The objective of this review is analyze and systematize approaches to selecting diseases/conditions for baseline (pilot) implementation of value-based healthcare, as used by leading international project initiatives. We analyzed materials from three initiatives: the International Consortium for Health Outcomes Measurement (ICHOM), projects supported by the United Nations Institute for Training and Research (UNITAR), and the Health Outcomes Observatory (H2O). A qualitative content analysis followed by thematic grouping of the identified criteria was used. Five key categories of criteria used in selecting the areas for value-based healthcare implementation were systematized: 1) epidemiological and medical-social significance; 2) potential for improving the quality and effectiveness of medical care; 3) organizational and technical feasibility; 4) quality and practical applicability of data set; 5) engagement of key stakeholders. Approaches to selecting diseases for value-based healthcare piloting are adaptive and project-oriented. They largely depend on operational goals and context of a specific initiative. Identifying and systematizing the key criteria form methodological basis for planning further research and substantiating disease prioritization within value-based healthcare implementation at the level of certain medical organizations and other project initiatives.
- 17 March 2026
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 48 (1) , 48-58
Comparison of disease prioritization approaches for piloting value-based healthcare. Experience of international projects
Despite multiple international projects aimed at developing standards and pilot introduction of value-based healthcare, there is no systematic understanding of approaches for selection of priority diseases or conditions at baseline phase of implementing this model. The objective of this review is analyze and systematize approaches to selecting diseases/conditions for baseline (pilot) implementation of value-based healthcare, as used by leading international project initiatives. We analyzed materials from three initiatives: the International Consortium for Health Outcomes Measurement (ICHOM), projects supported by the United Nations Institute for Training and Research (UNITAR), and the Health Outcomes Observatory (H2O). A qualitative content analysis followed by thematic grouping of the identified criteria was used. Five key categories of criteria used in selecting the areas for value-based healthcare implementation were systematized: 1) epidemiological and medical-social significance; 2) potential for improving the quality and effectiveness of medical care; 3) organizational and technical feasibility; 4) quality and practical applicability of data set; 5) engagement of key stakeholders. Approaches to selecting diseases for value-based healthcare piloting are adaptive and project-oriented. They largely depend on operational goals and context of a specific initiative. Identifying and systematizing the key criteria form methodological basis for planning further research and substantiating disease prioritization within value-based healthcare implementation at the level of certain medical organizations and other project initiatives.
- Open Access
- 6 August 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (2) , 219-231
Results of adaptation of tools for standardizing value-based outcomes: analysis of ICHOM Standard Sets
Background. Value-based healthcare (VBHC) is a model of medical care that focuses on analyzing treatment outcomes and takes into account patient-relevant results (values), clinical effectiveness, and economic costs. Although standardized assessment systems exist, such as those developed by the International Consortium for Health Outcomes Measurement (ICHOM), their practical application remains limited, slows the implementation of VBHC. The lack of unified methodologies reduces data comparability between healthcare organizations, hinders the identification of best practices, and ultimately impedes the practical realization of VBHC.Objective: To analyze and adapt standardized approaches for assessing VBHC parameters and the methodologies for their collection based on ICHOM sets.Material and methods. A comprehensive analysis was conducted on 49 ICHOM Standard Sets and 43 related publications in peer-reviewed journals. A structured study of the research objects was carried out, and potential barriers to the implementation of data collection methodologies by healthcare organizations were identified. Methods of qualitative content analysis and comparative data analysis were applied.Results. The article presents a structure of indicators for the assessment of VBHC. Particular attention is given to three key components of outcomes assessment: patient-oriented outcomes – patient-reported outcomes, clinical outcomes, and indicators of healthcare resource utilization. Standardized approaches to data collection were identified, each of which has its own limitations. Optimal monitoring timelines were determined, varying depending on the type of nosology. The results demonstrate that ICHOM standards provide a comprehensive framework for assessing value-based healthcare; however, they require adaptation to specific organizational conditions. The developed data categorization and presented conclusions provide a foundation for healthcare institutions to initiate the implementation of a value-based approach, with a focus on outcomes that matter to patients.Conclusion. The conducted analysis justifies the necessity of value-based healthcare research in accordance with the unified ICHOM Standard Sets. A unified methodology can provide a comprehensive and objective assessment of care effectiveness and foster a common understanding of the concept among all stakeholders. This approach will facilitate the transition from theory to global practice in value assessment in medicine. The next step in this direction should be the adaptation of data collection for specific sets, taking into account national characteristics and capabilities in Russia.
- 6 August 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (2) , 219-231
Open AccessResults of adaptation of tools for standardizing value-based outcomes: analysis of ICHOM Standard Sets
Background. Value-based healthcare (VBHC) is a model of medical care that focuses on analyzing treatment outcomes and takes into account patient-relevant results (values), clinical effectiveness, and economic costs. Although standardized assessment systems exist, such as those developed by the International Consortium for Health Outcomes Measurement (ICHOM), their practical application remains limited, slows the implementation of VBHC. The lack of unified methodologies reduces data comparability between healthcare organizations, hinders the identification of best practices, and ultimately impedes the practical realization of VBHC.Objective: To analyze and adapt standardized approaches for assessing VBHC parameters and the methodologies for their collection based on ICHOM sets.Material and methods. A comprehensive analysis was conducted on 49 ICHOM Standard Sets and 43 related publications in peer-reviewed journals. A structured study of the research objects was carried out, and potential barriers to the implementation of data collection methodologies by healthcare organizations were identified. Methods of qualitative content analysis and comparative data analysis were applied.Results. The article presents a structure of indicators for the assessment of VBHC. Particular attention is given to three key components of outcomes assessment: patient-oriented outcomes – patient-reported outcomes, clinical outcomes, and indicators of healthcare resource utilization. Standardized approaches to data collection were identified, each of which has its own limitations. Optimal monitoring timelines were determined, varying depending on the type of nosology. The results demonstrate that ICHOM standards provide a comprehensive framework for assessing value-based healthcare; however, they require adaptation to specific organizational conditions. The developed data categorization and presented conclusions provide a foundation for healthcare institutions to initiate the implementation of a value-based approach, with a focus on outcomes that matter to patients.Conclusion. The conducted analysis justifies the necessity of value-based healthcare research in accordance with the unified ICHOM Standard Sets. A unified methodology can provide a comprehensive and objective assessment of care effectiveness and foster a common understanding of the concept among all stakeholders. This approach will facilitate the transition from theory to global practice in value assessment in medicine. The next step in this direction should be the adaptation of data collection for specific sets, taking into account national characteristics and capabilities in Russia.